Four-week rapamycin treatment improves muscular dystrophy in a fukutin-deficient mouse model of dystroglycanopathy

BACKGROUND: Secondary dystroglycanopathies are a subset of muscular dystrophy caused by abnormal glycosylation of α-dystroglycan (αDG). Loss of αDG functional glycosylation prevents it from binding to laminin and other extracellular matrix receptors, causing muscular dystrophy. Mutations in a number...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Skelet Muscle
Autors principals: Foltz, Steven J., Luan, Junna, Call, Jarrod A., Patel, Ankit, Peissig, Kristen B., Fortunato, Marisa J., Beedle, Aaron M.
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2016
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4890530/
https://ncbi.nlm.nih.gov/pubmed/27257474
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13395-016-0091-9
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars